T he proarrhythmic potential of flecainide acetate, a class Ic antiarrhythmic agent, has been well documented in the last few years. 15 It is estimated to occur in 6.8 percent of the patients overall and was serious in 2.3 percent and lethal in 1 percent. 2 We herein report the findings in a patient with flecainide-induced incessant symptomatic ventricular tachycardia, in whom we observed a striking and immediate response to high-dose intravenous amiodarone, with total abolition of ventricular tachycardia.
CASE REPORT
A 62-year-old man with a history of anterior myocardial infarction and paroxysmal sustained ventricular tachycardia was admitted following the documentation of symptomatic (dizziness and presyncope) nonsustained ventricular tachycardia. He was receiving amiodarone (200 mg/day) and mexiletine (600 mg/day). Physical examination revealed mild signs of heart failure. The electrocardiogram revealed multiform premature ventricular complexes. The P-R interval and QRS duration were normal, as were the Q-T and U "Ic intervals (0.36 second and 0.34 second, respectively). A twodimensional echocardiogram showed a dilated and poorly contracting left ventricle.
In view of the ineffectiveness of the drugs, all prior antiarrhythmic therapy was withdrawn (two weeks). Therapeutic trials with quiuidine and propafenone were unsuccessful, with persistence of complex premature ventricular contractions and nonsustained ventricular tachycardia. Oral flecainide (100 mg twice daily) was administered without improvement. The dosage was then gradually increased every four days up to 200 mg twice daily. An increase in the number of complex premature ventricular contractions and nonsustained ventricular tachycardia was documented by Holter monitoring. There was no significant prolongation of the P-R, QRS and Q-T intervals and no electrolyte disturbances were detected.
After 48 hours of therapy with flecainide (400 mg/day), the patient developed almost incessant self-sustained ventricular tachycardia with two distinct morphologies and rates (Fig 1) . These two morphologies of ventricular tachycardia were different from the previously observed paroxysmal sustained and nonsustained ventricular tachycardia and were considered to be nonclinical. During a period of eight hours, the patient suffered recurrent episodes of sustained ventricular tachycardia despite therapy with intravenous lidocaine (100-mg bolus), bretylium tosylate (bolus of 5 mg/kg), and procainamide hydrochloride (stopped after 200 mg because of hypotension il llll iai iiii iiiiiiiiii FIGURE 1. Monitor lead showing ventricular tachycardia during therapy with flecainide, with two distinct morphologies and rates, necessary five times, and in one episode the ventricular tachycardia degenerated into ventricular fibrillation. The blood level of flecainide was not determined. Intravenous amiodarone (600 mg) was then infused over 20 minutes. There was a striking and total disappearance of ventricular tachycardia and premature ventricular contractions at the end of the infusion. During the next 24 hours the patient was given 2 g of amiodarone intravenously, and an oral loading dosage of 2 g/24 hours was started concomitantly. Except for one episode of ventricular tachycardia which occurred ten hours following the initiation of intravenous amiodarone and which we believe was due to a reduction in the dose of intravenous amiodarone, the patient remained free of arrhythmias. The dosage of amiodarone was gradually reduced every four days. Holter monitoring performed 3 and 14 days later documented less than ten premature ventricular contractions per hour and no episode of couplets or ventricular tachycardia.
DISCUSSION
Almost all antiarrhythmic drugs have also been shown to have proarrhythmic effects, and flecainide is no exception. Morganroth et al 2 reviewed the proarrhythmic potential of flecainide in 1,330 patients derived from various studies. Proarrhythmic events occurred in 6.8 percent of the patients overall and were serious in 2.3 percent and lethal in 1 percent. The incidence of such events varies according to the types of patients treated. It was significantly higher in patients with a history of sustained ventricular tachycardia (6.6 percent) than in patients with nonsustained ventricular tachycardia (0.9 percent) or premature ventricular contractions only (zero). Higher rates were also observed in patients with severe compromised left ventricular function and patients who were receiving a higher dosage. Our patient had a history of ventricular tachycardia and severe left ventricular dysfunction and was therefore prone to develop proarrhythmic events.
Although there have been many publications on flecainide-induced ventricular tachycardia, there is still no definite therapy for this condition. In the few detailed reported cases with incessant ventricular tachycardia, 34 recurrent cardioversions with discontinuation of flecainide was the only effective therapy. Horowitz et al 3 described a patient in whom vasopressor drugs were required during seven hours of flecainide-induced ventricular tachycardia, after which the patient underwent successful cardioversion. Spivack et al" described a patient with incessant ventricular tachycardia in whom repeated cardioversion and overdrive suppression trials were unsuccessful, and the patient died. In our patient, we observed a striking and immediate effect of intravenous amiodarone following a period of eight hours of recurrent symptomatic ventricular tachycardia which was refractory to various antiarrhythmic agents. Since amiodarone has a long half-life and since the patient received this drug orally (stopped four weeks before intravenous administration), it is possible that some amiodarone was still present in the body, therefore potentiating the effect of intravenous amiodarone.
It is of note that lidocaine, bretylium, and procainamide were given only during the first two hours and in simple boluses and with no maintenance infusion. It is therefore highly unlikely that these drugs may have contributed to the favorable response obtained with the intravenous amiodarone. It is also probable that the blood level of flecainide had decreased significantly at the time of intravenous administration of amiodarone; however, the striking disappearance of "all" arrhythmias within 20 minutes of intravenous infusion of amiodarone supports the assumption that the beneficial antiarrhythmic effect was due to the drug and not to the discontinuation of flecainide.
Rapid suppression of complex ventricular arrhythmias with high-dose intravenous amiodarone has recently been reported. Mostow et al 5 reported 85 percent reduction of ventricular tachycardia in seven patients within 48 hours (total dose, 1,948 to 4,637 mg). The same group used highdose oral amiodarone (between 800 and 2,000 mg two to three times daily) and demonstrated significant reduction in ventricular tachycardia beginning the second day. 6 In all of these high-dose protocols, there were no significant hemodynamic alterations except for two patients with severe left ventricular dysfunction. In our patient, we used a similar rapid intravenous and oral loading protocol and observed no hemodynamic deterioration, despite the severe left ventricular dysfunction. Such rapid abolition of flecainideinduced incessant ventricular tachycardia has not been previously described, and therefore we believe that a similar protocol of amiodarone should be tested in future cases of this severe arrhythmia. 
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Based on the in vitro synergism between TIMENTIN and aminoglycosides against certain strains of Pseudomonas aeruginosa, combined therapy has been successful especially in patients with impaired host defenses Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted as indicated. 
